You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 164 No. 22, Dec 13/27, 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Asthma
 •Chronic Obstructive Pulmonary Disease
 •Women's Health
 •Women's Health, Other
 •Allergy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Postmenopausal Asthma: The Estradiol 11{beta}-Hydroxysteroid Dehydrogenase Connection

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Barr and colleagues1 reported that postmenopausal female hormone therapy is associated with an increased rate of onset of asthma. They noted that the incidence of asthma usually decreases with the onset of menopause and that estrogens may exert proinflammatory effects.

In their discussion, their comments on common proinflammatory mechanisms that activate asthma failed to include the possibility that a decrease in the anti-inflammatory protection provided by cortisol might allow asthma to develop. Cortisol is an extremely powerful anti-inflammatory agent that may be protective against the development of chronic inflammation.2

Until recently, plasma cortisol concentrations were considered to provide a clinically relevant measure of cortisol availability and adequacy. It is now clear that intracellular cortisol concentrations are more important and are regulated, in a tissue-specific manner, by the 11{beta}-hydroxysteroid dehydrogenase type I isoenzyme.3 Furthermore, it has been demonstrated that estrogen is capable of inhibiting the activity of this enzyme, thereby . . . [Full Text of this Article]


AUTHOR INFORMATION
Paul G. Cohen, MD; John M. Holbrook, PhD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.